Articles from Avitia

Avitia, an AI-powered cancer diagnostics company advancing access to fast and affordable molecular testing, today announced its entry into Thailand through a partnership with The Chitrapatima Foundation, a charitable foundation that was established in 1973 at the headquarters of the Fourth Army under the leadership of General Sant Chitrapatima and his wife, Khun Ying Varee Chitrapatima — a Lady-in-Waiting to Her Majesty the Queen. The Foundation, which develops projects to improve the well-being of the Thai people, will establish Thailand’s first advanced liquid biopsy cancer testing ecosystem for hospitals and communities. Leveraging Avitia’s AI-powered precision diagnostics, Thai people can receive more precise treatment guidance through a simple blood test. The initiative supports the Foundation’s mandate to advance the nation’s health through biomedical innovation, improving the availability of advanced cancer care by removing financial and geographical barriers that have historically limited access.

Avitia, an AI company providing end-to-end testing solutions to rapidly identify cancer mutations and applicable treatments, today announced its business launch and $5M seed investment from PacBridge Capital Partners (“PacBridge”). With Avitia’s platform, laboratories and clinicians now have access to advanced molecular testing directly on-site no matter where they are located. This technology will allow a healthcare team to accurately obtain cancer insights and begin treating patients faster — all at reduced costs compared to existing send-out alternatives. With this capital, Avitia will expand into new markets and enhance its platform’s capabilities. Avitia’s technology is currently used by partners in Canada, the United States, and Southeast Asia. With over 40,000 life-saving cancer mutation tests already run using this technology, Avitia affirms its role as a trusted partner in transforming global cancer care.